AcelRx Pharmaceuticals is a pharmaceutical company. Co.'s product candidates, focused on the treatment of acute pain are, DSUVIA™ (known as DZUVEO outside of the U.S.), and ZALVISO®, each of which utilizes sublingual sufentanil, delivered via a non-invasive route of sublingual administration, for use in medically supervised settings. DSUVIA is a non-invasive investigational product candidate consisting of sufentanil tablets delivered sublingually by a healthcare personnel using a disposable, pre-filled, single-dose applicator. ZALVISO consists of sufentanil sublingual tablets delivered by the ZALVISO System, a needle-free, handheld, patient-administered, pain management system. We show 36 historical shares outstanding datapoints in our coverage of ACRX's shares outstanding history.
Understanding the changing numbers of ACRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRX by allowing them to research ACRX shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
